FEOBV F-18
Apathy
University Hospital, BordeauxSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
7 Active assets in the Apathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Methylphenidate Sunnybrook Health Sciences Centre | Phase 4 | BBB |
Tvp-1012 University Hospital, Clermont-Ferrand | Phase 4 | BB |
Rivastigmine University Hospital, Lille | Phase 3 | B |
Modafinil Brown University | Phase 3 | B |
Rotigotine University Hospital, Grenoble | Phase 3 | B |
View all 13 →
Same molecule, other indications
FEOBV F-18 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →